Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

被引:261
|
作者
Zhu, Xinxin [1 ]
Lang, Jinghe [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
soluble; PD-1; PD-L1; tumor immunity; biomarker; CELL LUNG-CANCER; DEATH-LIGAND; PROGRAMMED DEATH-1; ANTITUMOR IMMUNITY; T-CELLS; HEPATOCELLULAR-CARCINOMA; CLINICAL-SIGNIFICANCE; POOR-PROGNOSIS; PD-1/PD-L1; BLOCKADE; CIRCULATING PD-L1;
D O I
10.18632/oncotarget.18311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The membrane-bound molecules programmed death 1 (PD-1) and its ligand PD-L1 (PD-1/PD-L1) belong to the immune checkpoint pathway. PD-1 pathway downregulates effector T cells in immune response, thereby causing immune suppression. Recent studies have revealed that membrane-bound PD-1 and PD-L1 also have soluble forms. These soluble forms increase the complexity and diversity of the composition and function of the PD-1/PD-L1 signaling pathway. However, the exact roles of these molecules remain unknown. The objective of this systematic review was to elucidate the biological significance of soluble PD-1/PD-L1 in human cancers and evaluate whether they are potential diagnostic, therapeutic, or prognostic biomarkers. We expect to provide new clues for future research on soluble PD-1/PD-L1 pathway in human malignant tumors.
引用
收藏
页码:97671 / 97682
页数:12
相关论文
共 50 条
  • [31] The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
    Yang, Hui
    Wang, Kunlun
    Wang, Tao
    Li, Mengxi
    Li, Bingxu
    Li, Shenglei
    Yuan, Ling
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [32] POTENTIAL AS BIOMARKERS OF SOLUBLE PD-1 AND PD-L1 IN HEPATOCELLULAR CARCINOMA
    Kanzaki, Hiroaki
    Chiba, Tetsuhiro
    Kato, Naoya
    HEPATOLOGY, 2019, 70 : 1218A - 1218A
  • [33] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [34] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
    Saito, Hiroaki
    Kono, Yusuke
    Murakami, Yuki
    Shishido, Yuji
    Kuroda, Hirohiko
    Matsunaga, Tomoyuki
    Fukumoto, Yoji
    Osaki, Tomohiro
    Ashida, Keigo
    Fujiwara, Yoshiyuki
    ANTICANCER RESEARCH, 2018, 38 (01) : 107 - 112
  • [35] PD-1/PD-L1 in disease
    Kuol, Nyanbol
    Stojanovska, Lily
    Nurgali, Kulmira
    Apostolopoulos, Vasso
    IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
  • [36] Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
    Khan, Muhammad
    Zhao, Zhihong
    Arooj, Sumbal
    Fu, Yuxiang
    Liao, Guixiang
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [37] Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
    Meng, Xiangjiao
    Huang, Zhaoqin
    Teng, Feifei
    Xing, Ligang
    Yu, Jinming
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 868 - 876
  • [38] Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1
    Darabi, Sourat
    Braxton, David R.
    Eisenberg, Burton L.
    Demeure, Michael J.
    ONCOLOGY-NEW YORK, 2020, 34 (08): : 321 - 327
  • [39] Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer A Meta-Analysis
    Zhang, Yaxiong
    Kang, Shiyang
    Shen, Jianfei
    He, Jiaxi
    Jiang, Long
    Wang, Wei
    Guo, Zhihua
    Peng, Guilin
    Chen, Gang
    He, Jianxing
    Liang, Wenhua
    MEDICINE, 2015, 94 (06) : e515
  • [40] Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer
    Zhang, Ying
    Li, Jing
    Yang, Fan
    Zhang, Xiying
    Ren, Xiubao
    Wei, Feng
    JOURNAL OF LEUKOCYTE BIOLOGY, 2022, 112 (06) : 1591 - 1603